Minsi Liao
YOU?
Author Swipe
View article: VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION‐BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY
VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION‐BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY Open
Introduction: The CLL14 study has established fixed-duration treatment with the BCL2 inhibitor venetoclax and the CD20 antibody obinutuzumab (Ven-Obi) for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL). The aim…